Finance

Lists
CLYM:NASDAQ
Climb Bio Inc
US$ ९.३६
+०.६५%
(+०.०६०) 1D
नोभेम्बर १९, १४:४४:२२ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLYM...
Open
US$ ९.३६
High
US$ ९.६५
Low
US$ ८.९२
Mkt. cap
५४.९८ करोड
Avg. vol.
११.७४ लाख
Volume
२.५० लाख
52-wk high
US$ १८.३३
52-wk low
US$ १.६४
EPS
-US$ ०.८२
Beta
०.०४
Shares outstanding
५.८७ करोड
No. of employees
२९
Open
US$ ९.३६
High
US$ ९.६५
Low
US$ ८.९२
Mkt. cap
५४.९८ करोड
Avg. vol.
११.७४ लाख
Volume
२.५० लाख
52-wk high
US$ १८.३३
52-wk low
US$ १.६४
EPS
-US$ ०.८२
Beta
०.०४
Shares outstanding
५.८७ करोड
No. of employees
२९
News stories
From web sources and news partners
About Climb Bio Inc
CEO-
Employees२९
Founded२०१८
HeadquartersWellesley Hills, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 13 analysts giving stock ratings to CLYM in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CLYM in the last 3 months.
Highest
Current US$ ९.३६
US$ ४०.०० (+३२७.३५%)
Average
US$ २८.८३ (+२०८.०१%)
Lowest
US$ २३.०० (+१४५.७३%)
Analyst
Recommendation
Action
Price target
Projected
Date
Nevin Varghese
RBC Capital
Buy
Maintained
US$ २३.००
+१४५.७%
11/18/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
US$ २६.००
+१७७.८%
11/10/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ ३०.००
+२२०.५%
11/09/2026
Danielle Brill
Truist Financial
Buy
Maintained
US$ २५.००
+१६७.१%
11/06/2026
Laura Chico
Wedbush
Buy
Maintained
US$ २७.००
+१८८.५%
11/06/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$ २५.००
+१६७.१%
11/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
US$ ३५.००
+२७३.९%
11/05/2026
Julian Harrison
BTIG
Buy
Maintained
US$ ३२.००
+२४१.९%
11/04/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$ ४०.००
+३२७.४%
10/30/2026
David Hoang
Deutsche Bank
Buy
Initiated
US$ २८.००
+१९९.१%
10/20/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
US$ ३०.००
+२२०.५%
09/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
US$ २५.००
+१६७.१%
09/03/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/03/2026
Leland Gershell
Oppenheimer
Buy
Maintained
US$ १८.००
+९२.३%
08/07/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
06/24/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
06/12/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
US$ २१.००
+१२४.४%
05/06/2026
Geulah Livshits
Chardan Capital
Buy
Initiated
US$ २२.००
+१३५%
05/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
US$ १८.००
+९२.३%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.३७ करोड
९३.७३ लाख
९७.१४ लाख
१.१० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५५.५८ लाख
५८.३८ लाख
५६.४५ लाख
५८.४९ लाख
Operating expense
१.९३ करोड
१.५२ करोड
१.५४ करोड
१.६९ करोड
Total operating expenses
१.९३ करोड
१.५२ करोड
१.५४ करोड
१.६९ करोड
Operating income
-१.९३ करोड
-१.५२ करोड
-१.५४ करोड
-१.६९ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.७५ करोड
-१.३७ करोड
-१.३५ करोड
-१.४६ करोड
EBT excluding unusual items
-१.७५ करोड
-१.३७ करोड
-१.३५ करोड
-१.४६ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.७५ करोड
-१.३७ करोड
-१.३५ करोड
-१.४६ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.२६
-०.२०
-०.१८
-०.१८
Interest and investment income
१८.२६ लाख
१५.१४ लाख
१८.५५ लाख
२३.२५ लाख
Interest expense
-
-
-
-
Net interest expenses
१८.२६ लाख
१५.१४ लाख
१८.५५ लाख
२३.२५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.९३ करोड
-१.५२ करोड
-१.५३ करोड
-१.६७ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू